The Role of Genetic Factors in the Development of Idiopathic Osteoarthritis of the Knee in the Kazakh Population

March 13, 2023 updated by: Ildar Fakhradiyev, Asfendiyarov Kazakh National Medical University

Preventive and Personalized Medicine (2021-2023)

The purpose of this study is to identify genetic determinants of susceptibility to idiopathic osteoarthritis of the knee . It will assist in predicting individual risks of disease progression and would help to clarify pathophysiologic mechanisms of idiopathic osteoarthritis of the knee

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Kazakhstan
      • Almaty, Kazakhstan
        • Scientific center of traumatology and orthopedics named after academician Batpenova ND

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 68 years (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Persons of Kazakh nationality

Description

Inclusion Criteria:

  1. Patients with bilateral idiopathic gonarthrosis aged 18 to 65 years;
  2. Representatives of the Kazakh ethnic group up to the 3rd generation;
  3. Hereditary history of arthrosis;
  4. Persons who are able and willing to provide written informed consent;

Exclusion Criteria:

  1. Patients with bilateral idiopathic gonarthrosis under 18 years of age and over 65 years of age;
  2. Representatives of other ethnic groups;
  3. Representatives of the Kazakh ethnic group less than 3 generations;
  4. No family history of bilateral idiopathic gonarthrosis;
  5. Patients with an acute period of the inflammatory process (laboratory and clinical signs);
  6. Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent;
  7. Pregnant or lactating women;
  8. Tuberculosis of any localization in the active phase and in history;
  9. Severe and decompensated diseases of the liver and kidneys, cardiovascular system;
  10. Severe and decompensated course of endocrine diseases;
  11. Autoimmune diseases;
  12. Systemic diseases;
  13. Oncological diseases;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Experimental group:
patients with idiopathic osteoarthritis of the knee
Genetic: SNP analysis of the DNA
SNP analysis of the DNA obtained from peripheral blood sample
Control group
patients without idiopathic osteoarthritis of the knee
Genetic: SNP analysis of the DNA
SNP analysis of the DNA obtained from peripheral blood sample

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
enotyping for the SNP associated with liver cirrhosis
Time Frame: 1 year
Genotype frequency of SNP in the study genes of participants and control participants.
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Asfendiyarov Kazakh National Medical University

Investigators

  • Principal Investigator: Olzhas Bekarisov, PhD, Scientific center of traumatology and orthopedics named after academician Batpenova ND

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 30, 2022

Primary Completion (Actual)

January 20, 2023

Study Completion (Actual)

January 20, 2023

Study Registration Dates

First Submitted

October 21, 2021

First Submitted That Met QC Criteria

October 26, 2021

First Posted (Actual)

October 27, 2021

Study Record Updates

Last Update Posted (Actual)

March 14, 2023

Last Update Submitted That Met QC Criteria

March 13, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1191

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Idiopathic Osteoarthritis

Clinical Trials on SNP analysis of the DNA

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe